Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Misses Estimates By $0.58 EPS

Share on StockTwits

Personalis (NASDAQ:PSNL) announced its earnings results on Tuesday. The company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.58), Briefing.com reports. The company had revenue of $15.80 million for the quarter, compared to analysts’ expectations of $14.92 million. Personalis’s revenue for the quarter was up 79.5% compared to the same quarter last year. Personalis updated its FY 2019 guidance to EPS.

Shares of NASDAQ PSNL opened at $19.71 on Wednesday. The business has a fifty day moving average of $21.50. Personalis has a 1-year low of $14.25 and a 1-year high of $31.88.

In other Personalis news, Director Ken Ludlum purchased 70,000 shares of the business’s stock in a transaction on Monday, June 24th. The shares were purchased at an average cost of $17.00 per share, with a total value of $1,190,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

A number of equities analysts recently weighed in on PSNL shares. CIBC started coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 target price for the company. Morgan Stanley started coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “overweight” rating and a $28.00 target price for the company. Cowen started coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating for the company. Bank of America started coverage on shares of Personalis in a research note on Monday, July 15th. They issued a “neutral” rating and a $27.00 target price for the company. Finally, Oppenheimer started coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Personalis currently has an average rating of “Buy” and a consensus target price of $28.25.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Further Reading: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.